2,849
Views
17
CrossRef citations to date
0
Altmetric
Pulmonary Medicine

Pathophysiology of respiratory failure in patients with osteogenesis imperfecta: a systematic review

, , , , , & show all
Pages 1676-1687 | Received 30 Jul 2021, Accepted 09 Sep 2021, Published online: 27 Sep 2021

Abstract

Introduction

Respiratory failure is a major cause of death in patients with Osteogenesis Imperfecta. Moreover, respiratory symptoms seem to have a dramatic impact on their quality of life. It has long been thought that lung function disorders in OI are mainly due to changes in the thoracic wall, caused by bone deformities. However, recent studies indicate that alterations in the lung itself can also undermine respiratory health.

Objectives

Is there any intrapulmonary alteration in Osteogenesis Imperfecta that can explain decreased pulmonary function? The aim of this systematic literature review is to investigate to what extent intrapulmonary or extrapulmonary thoracic changes contribute to respiratory dysfunction in Osteogenesis Imperfecta.

Methods

A literature search (in PubMed, Embase, Web of Science, and Cochrane), which included articles from inception to December 2020, was performed in accordance with the PRISMA guidelines.

Results

Pulmonary function disorders have been described in many studies as secondary to scoliosis or to thoracic skeletal deformities. The findings of this systematic review suggest that reduced pulmonary function can also be caused by a primary pulmonary problem due to intrinsic collagen alterations.

Conclusions

Based on the most recent studies, the review indicates that pulmonary defects may be a consequence of abnormal collagen type I distorting the intrapulmonary structure of the lung. Lung function deteriorates further when intrapulmonary defects are combined with severe thoracic abnormalities. This systematic review reveals novel findings of the underlying pathological mechanism which have clinical and diagnostic implications for the assessment and treatment of pulmonary function disorders in Osteogenesis Imperfecta.

    KEY MESSAGES

  • Decreased pulmonary function in Osteogenesis Imperfecta can be attributed to primary pulmonary defects due to intrapulmonary collagen alterations and not solely to secondary problems arising from thoracic skeletal dysplasia.

  • Type I collagen defects play a crucial role in the development of the lung parenchyma and defects, therefore, affect pulmonary function. More awareness is needed among physicians about pulmonary complications in Osteogenesis Imperfecta to develop novel concepts on clinical and diagnostic assessment of pulmonary functional disorders.

At a glance

Scientific knowledge on the topic

Acute and chronic respiratory failure are major causes of death in patients with Osteogenesis Imperfecta. Aberrant type I collagen causes bone demineralization, deformities, and fractures, which in turn results in structural abnormalities of the chest wall and spine, limiting the pulmonary function. Treatment of Osteogenesis Imperfecta focuses on preventing fractures and correcting bone deformities, but the pulmonary disease is often ignored until breathing problems become severe. Type I collagen is found in many connective tissues, including the interstitial parenchyma of the mammalian lung. The question that arises is to what extent abnormal collagen contributes to the decreased pulmonary function of patients with OI. We performed a systematic review to examine all available knowledge on the pathogenesis of lung disease in OI.

What this study adds to the field

Type I collagen defects play a crucial role in the development of the lung parenchyma and defects, therefore, affect pulmonary function. These findings will hopefully lead to more awareness among physicians about pulmonary complications in OI and novel concepts on clinical and diagnostic assessment of pulmonary disorders. We suggest pulmonary function and lung diffusion testing in OI patients even in the absence of thoracic malformations.

Introduction

Osteogenesis Imperfecta (OI) is a rare inheritable condition commonly caused by mutations in genes (COL1A1 and COL1A2) encoding collagen type I which is essential for healthy bone formation. Clinically, OI is primarily characterized by bone fragility, small stature, skeletal deformity, ligament laxity, blue sclerae, dentinogenesis imperfecta, hearing impairment, and cardiopulmonary disease. According to the Sillence classification OI type I is the least severe form and is mostly characterized by an insufficient level of synthesized collagen leading to a limited number of fractures. OI type II, III, and IV are mainly characterized by structural alterations in type I collagen; OI type II is perinatally lethal, OI type III is characterized by progressive deformations, multiple fractures, very short stature, and wheelchair dependency and type IV is relatively mild with a variable number of fractures [Citation1–6].

Although bone fragility is the most common patient issue, extraskeletal manifestations also play a crucial role in the lives of patients with OI. Respiratory conditions are clinically often ignored until breathing problems become severe, even though the sparse literature on this topic supports that OI patients suffer from restrictive lung disease with dyspnoea and impaired pulmonary ventilation. Spirometry has been used as a primary measure to evaluate pulmonary function in OI, showing increasingly restrictive lung disease in correlation with the severity of OI. These patients are more vulnerable to viral and bacterial infections of upper and lower airways, chronic infection, and the formation of bronchiectasis [Citation7–13].

The clinical urgency of lung disease in OI is also evident by the fact that respiratory failure appears to contribute significantly to morbidity and decreased quality of life in OI patients [Citation14–17]. A cohort study in Denmark showed that OI patients have a subhazard ratio for death by the respiratory disease which is three times higher than in the reference population [Citation15]. In OI type II many case reports describe perinatal death related to pulmonary hypoplasia and respiratory failure [Citation18–22]. Moreover, the study of Yonko et al. on the quality of life in OI concluded that respiratory symptoms negatively impact psychosocial well-being and limit daily physical activity. These limitations occur regardless of their OI type, age, or scoliosis and reflect the dramatic impact of respiratory status on the quality of life for people with OI [Citation16].

Type I collagen is a major constituent of the connective tissue of the lungs which is particularly found in bronchi, blood vessels, and the alveolar interstitium. Lung function greatly depends on collagen and elastin, which provide elastic strength to facilitate respiratory mechanics. Collagen type I defects in OI can therefore affect the lung structure and function [Citation23–28].

All these data underline the necessity to examine collagen defects as an intrinsic factor in the aetiology of lung problems in OI patients, based on which clinical guidelines can be adjusted to improve critical points in the respiratory care of OI. This systematic literature review aims to investigate to what extent intrapulmonary or extrapulmonary thoracic wall changes contribute to respiratory dysfunction in OI patients in an effort to raise awareness about its pathophysiology and unmet clinical needs.

Methods

The literature was systematically reviewed to identify publications on lung pathogenesis in Osteogenesis Imperfecta. This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-statement. To identify all relevant publications, systematic searches were conducted in the bibliographic databases PubMed, Embase.com, Web of Science, and Cochrane from inception up to 7 December 2020, in collaboration with a medical information specialist.

Search terms included controlled terms from MeSH in PubMed and Emtree in Embase.com in addition to free-text terms. The following terms were used (including synonyms and closely related words): “Osteogenesis imperfecta”, “Brittle bone dis*”, “Respiratory insufficiency”, “Pulmonary function”, “Respiration/pathophysiology”. The search was performed without date or language restriction. Full search strategies for all databases can be found in the Supplementary Material.

Study selection

After deduplication, a total of 1111 papers were identified. First, all titles were screened for eligibility by two researchers (SS and EE) after which all remaining abstracts were screened. In case of disagreement, the consensus was reached through dialogue. A total of 52 studies were included for full-text analysis. Thirty-four studies were excluded ().

Figure 1. Flow diagram of the systematic review following the PRISMA guidelines.

Figure 1. Flow diagram of the systematic review following the PRISMA guidelines.

Inclusion criteria

The following inclusion criteria were used: (1) studies published in English; (2) studies including patients with Osteogenesis Imperfecta; (3) studies adequately describing the cause of the lung problem; (4) studies describing OI in children, adults, or mice; (5) studies published as an original article; (6) full-text availability; and (7) all types of study design.

Exclusion criteria

The following exclusion criteria were used: (1) studies published before 1970; (2) Systematic reviews; (3) Cole Carpenter syndrome; and (4) Bruck syndrome.

Quality assessment

Quality assessment was performed on all included articles describing lung problems. The Quality assessment was independently performed by two researchers (SS and EE). In case of disagreement, the consensus was reached through dialogue. Most of the articles consisted of case-control, cohort, cross-sectional studies, and case series (82%). These articles were assessed using the Study Quality Assessment Tool created by NHLBI. The remaining 18% consisted of case reports. The quality of the reports was assessed according to the method described by Murad et al. [Citation29].

Results

Intrapulmonary disease in OI mouse models

To date, four studies have evaluated lung parenchyma changes in OI mice [Citation11,Citation30–32]. These studies on animal models of OI, representing different OI types and genetic causes, all share post-natal primary defects in the lung parenchyma that are reminiscent of emphysematous changes (). In all studies, a diffuse increase in alveolar airway space and a loss of the alveolar walls was described. In three of these studies, the mean linear intercept length (Lm) was used to quantify the size of distal airspaces in OI and wild-type (WT) mice. There was a significant increase in the Lm value of the lungs of OI mice compared to the control mice. These alterations caused changes in the breathing pattern of the mice and affected their respiratory mechanics [Citation11,Citation32].

Table 1. Summary of mouse model characteristics.

Multiple lung abnormalities of the lung connective tissue in OI mice have been reported due to different causes (). Baglole et al. suggested a complex and multifaceted cause for respiratory complications, concluding that the distal airspace enlargement associated with emphysema is potentially a direct consequence of the dysfunctional type I collagen, which results in a loss of pulmonary elastic recoil [Citation30]. Baldridge et al. concluded that lung defects in individuals with OI may be the primary result of abnormal collagen synthesis and not secondary to skeletal abnormalities [Citation31]. Dimori et al. suggested that the collagen over modifications observed in CrtapKO mice and the potential resulting alterations in cross-linking of the collagen fibrils in OI may significantly weaken the strength of the alveolar wall and its ability to withstand the mechanical stress and strain that are typical of each breathing cycle.

This early rupture of the alveolar wall or developmental dysplasia of the lung parenchyma with defective alveolarization accounted for the alterations in the breathing pattern of the mice and altered respiratory mechanics [Citation11,Citation32].

Extrapulmonary causes of abnormal lung function in OI patients

Extrapulmonary causes of abnormal lung function have been reported in eight studies of OI patients in whom the restrictive lung function pattern is related to the sternal, rib cage, or vertebral deformities (). Lo Mauro et al. studied the structural modifications of the rib cage and the breathing pattern of OI patients. A close relationship has been suggested between the restrictive respiratory pattern of OI and the severity of the disease, especially in OI type III in which sternal deformities appear to severely affect respiratory function. This is caused by the combination of pectus carinatum, brittle ribs, and spinal deformity that mechanically affect muscle function of the rib cage [Citation8,Citation33].

Table 2. Patients characteristics of studies supporting extrapulmonary causes of abnormal lung function in OI patients.

Wekre et al. and Widmann et al. both support that compromised OI pulmonary function shows a significant correlation with spinal deformities, especially with thoracic scoliosis [Citation12,Citation13]. Instead, Gimeno et al. found that decreased respiratory function in OI patients is related to an anatomic configuration characterized by more horizontally aligned ribs, which indicates that the alteration of the ventilation largely depends on the position of the ribs rather than the shape of the spine [Citation34]. One study also showed the absence of abnormalities in ventilation-perfusion relationships based on arterial blood gas measurements [Citation7]. shows two reports of thoracic elongation and surgery which improved pulmonary function in OI type IV patients, implicitly supporting the extrinsic role of thoracic malformations in lung function disorders [Citation35,Citation36].

Table 3. Lung and chest abnormalities after surgery.

Observational studies and intrinsic lung disease

offers an overview of the lung function in relation to chest abnormalities in OI patients, described in seven studies that support the hypothesis that impaired lung function is intrinsic to OI. This corroborates the findings in the OI mouse models, demonstrating post-natal primary defects in the lung parenchyma. Abnormal or insufficient collagen type I was proposed as the underlying cause of the pulmonary disease. Bronheim et al. found no correlation between the largest spinal curve and the FEV1/FVC ratio in 30 patients, supporting that decreased respiratory function may be an intrapulmonary consequence of altered collagen type I [Citation37]. Khan et al. also failed to detect an association between decreased pulmonary function and the severity of scoliosis, suggesting that restrictive lung function is caused by factors inherent in OI and not exclusively by thoracic cage deformities [Citation38]. Thiele et al. suggested that type I collagen alterations directly cause pathological changes in heart and lung tissue and that the physiopathology of lung disease is independent of skeletal dysplasia [Citation11].

Table 4. Patients characteristics of the studies supporting intrapulmonary causes of abnormal lung function in OI patients.

Three case reports described histological analysis of lung autopsy findings in OI type II patients, suggesting a possible role for defective procollagen type I synthesis in pulmonary airway development [Citation19,Citation20,Citation22]. Morikawa et al. reported an interesting case of a 19-year-old OI patient with diffuse pulmonary ossification which probably occurred during repair of alveolar damage due to decreased collagen type I production [Citation39].

Discussion

Respiratory failure is a major cause of death in patients with Osteogenesis Imperfecta, one of the most common inherited connective tissue disorders. Acute or chronic respiratory failure has been correlated to the severity of the OI disease [Citation14,Citation15,Citation17]. However, the underlying mechanism and pathophysiology have received relatively little attention. Little is known about whether and how OI can affect intrapulmonary tissues beyond its known effect on the thoracic skeleton. Research and treatment for OI have almost been exclusively focussed on fracture prevention, correction of bone deformities while other complications, such as hearing loss, dental problems, and pain relief are rarely addressed. Respiratory problems seem to receive particular attention only at a late stage when they have become a clinical problem. As a result, to date, there are no established international protocols for follow-up pulmonary surveillance or treatment of pulmonary manifestations in patients with OI.

To our knowledge, this is the first systematic review to examine the hypothesis that the cause of lung disease in OI may extend beyond thoracic skeleton deformities. This review identifies different potential causes of respiratory failure in OI and presents a new concept and perspective for care and research on pulmonary problems in OI. This review shows that in OI mice, changes in the lung parenchyma are specifically indicative of emphysematous changes [Citation11,Citation30–32]. These mice studies described enlarged alveolar airspaces, that may be due to either destruction of lung tissue (emphysema in the stricter sense) or abnormal growth of lung tissue (a kind of dysplasia). These defects have been attributed to the compromised type I collagen which consists of a major tissue component of mammalian lungs, found in bronchi, blood vessels, and within the alveolar interstitium [Citation28,Citation40]. Collagen type I is also known to be fundamental to the maintenance of lung structure and function due to its ability to effectively respond to mechanical stress during ventilation [Citation26,Citation28,Citation40,Citation41]. However, these preclinical studies are not exempt from limitations. These studies represent a limited number of OI types and genetic causes, thus findings from these models cannot be extrapolated to every type of OI. In particular, the Col1a1Jrt/+ model simulates severe dominant OI, Crtap knockout mice are a model of recessive OI and Aga2 mice recapitulate OI type II and III. Nevertheless, these four animal studies reveal valuable insight in lung histology indicating that the affected primary lung parenchyma defect in OI may play a greater role than previously suspected.

The presented studies reveal a dichotomy in the perspective and findings of the reported studies in patients. Eight studies reported that altered respiratory function in OI is related to the anatomic configuration and the severity of the disease [Citation7,Citation8,Citation12,Citation13,Citation33–36]. These studies show a clear correlation between thoracic malformations and pulmonary function parameters but did not rule out a concomitant intrapulmonary cause of the lung disease. On the contrary, there are also seven clinical studies supporting the hypothesis that impaired lung function is intrinsic to OI, meaning that altered type I collagen can play a crucial role in the alteration of the interstitium of the lung parenchyma, leading to restrictive or obstructive disease. These clinical studies are restricted by the small number of participants and the limited number of histological examinations that support the hypothesis of altered lung parenchyma. However, the post-mortem biopsy described in various case reports of severe human OI type II support that patient death was caused by reduced lung growth, diffuse alveolar damage, and immature acinar development.

We support that the underlying collagen defect plays a crucial role in the development and organization of the lung parenchyma in patients with OI, especially in patients with a structural alteration of type I collagen (OI type III and IV). However molecular diagnosis of patients was not performed in these studies which may help to ascertain the type of collagen defect. Interestingly, all examined OI mouse models with primary defects in the lung parenchyma shared structural alterations in collagen type I. We await future studies to show if that is also the case in cases of only reduced collagen production (less severe OI type I).

Many clinical studies used lung function examination as the main outcome. Patients with OI type I can have a normal lung function when the arm span is used to calculate the predicted values [Citation9,Citation12]. In type III and IV, the restriction is often found in both children and adults. The restriction is either proven by a low TLC or suggested by a reduced (F)VC or high FEV1/FVC (the latter denoted as ‘restrictive physiology’) ( and ). Limited data on the RV show a normal or a slightly decreased RV in most subjects [Citation7,Citation8,Citation13]. Only in some patients, with kyphoscoliosis, the RV was increased. Data on the FRC (functional residual capacity) are also limited. In one of the larger studies, the FRC was reduced in type III and IV (mean values 61 and 75% of predicted, respectively) [Citation8]. The transfer factor of the lung for CO (TLCO) was found to be either normal or increased [Citation38]. In addition to chest wall restriction, lung function may be affected by intrapulmonary factors, such as ground-glass opacities, atelectasis, or scarring that have been observed by CT-scan [Citation38]. In the latter study, emphysema was only found in one out of 29 patients (in the form of paraseptal emphysema). On the other hand, studies in mice indicate that emphysema can occur in OI (). Emphysema was also found in the lung tissue of deceased neonates with type II disease (). The histology of the 19-year-old OI patient who underwent VATS also showed emphysematous changes, along with haemorrhagic areas and dendritic-shaped ossifications (). We, therefore, suggest that the occurrence of emphysema is possible in patients with OI which necessitates the use of more test and histological examinations (Supplementary Figure 2).

The question remains whether emphysematous changes are compatible with the restrictive lung function that is mostly found in patients with advanced disease. Emphysema tends to enlarge the lung volume because of high lung compliance [Citation42]. We suppose that this effect can be masked by a low chest wall compliance, especially in the case of severe scoliosis, although kyphosis or other chest wall deformities may also contribute [Citation43].

Our expert recommendation, based on our review assessment, is the monitoring of respiratory functions by measuring both spirometric parameters (including ERV) and the single-breath CO-transfer with Helium dilution; this is suggested at the initial assessment and the yearly follow-ups of patients with qualitative collagen alterations, and every 3 years in patients with quantitative collagen alterations. Spirometry in patients with thoracic deformities or in patients who are unable to stand should be corrected for body height and arm span height. In patients with type III and IV also the spine curvature and the chest wall deformities should be carefully monitored. To prevent serious respiratory complications in OI patients, difficulties in breathing and respiratory infections should be treated immediately, and patients should be regularly vaccinated against influenza. Our recommendation also includes monitoring of the patients by a multidisciplinary team, including a pulmonologist and cardiologist [Citation44].

In conclusion, pulmonary function in OI patients should be carefully monitored even in the absence of sternal, rib cage, or vertebral deformities. Reduced lung function may deteriorate in relation to the rib cage or vertebral deformities but this is likely not the only cause of pulmonary disease in OI patients. Type I collagen defects may have a crucial role in the development of lung parenchyma in OI patients, leading to lung disease. Spirometric parameters should always be corrected based on height and complemented with the examination of lung physiology. Further research on this topic is needed to improve knowledge of the pathogenesis of OI pulmonary alterations to identify patient risk groups and suitable therapeutic targets to optimize clinical management for the prevention of morbidity and mortality in OI.

Author contributions

All authors were involved in study conception/design data analysis and/or interpretation and in writing/critical review of draft versions of this manuscript and all approved the final version for submission and publication.

Supplemental material

Supplemental Material

Download ()

Disclosure statement

The authors declare that they have no conflicts of interest.

Data availability statement

There is no raw data associated with this systematic review. The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

References

  • Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–116.
  • van Dijk FS, Cobben JM, Kariminejad A, et al. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromol. 2011;2(1):1–20.
  • Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164(6):1470–1481.
  • Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–381.
  • Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052.
  • Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657–1671.
  • Falvo KA, Klain DB, Krauss AN, et al. Pulmonary function studies in osteogenesis imperfecta. Am Rev Respir Dis. 1973;108(5):1258–1260.
  • LoMauro A, Pochintesta S, Romei M, et al. Rib cage deformities alter respiratory muscle action and chest wall function in patients with severe osteogenesis imperfecta. PLOS One. 2012;7(4):e35965.
  • Takken T, Terlingen HC, Helders PJ, et al. Cardiopulmonary fitness and muscle strength in patients with osteogenesis imperfecta type I. J Pediatrics. 2004;145(6):813–818.
  • Tam A, Chen S, Schauer E, et al. A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clin Genet. 2018;94(6):502–511.
  • Thiele F, Cohrs CM, Flor A, et al. Cardiopulmonary dysfunction in the osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms. Hum Mol Genet. 2012;21(16):3535–3545.
  • Wekre LL, Kjensli A, Aasand K, et al. Spinal deformities and lung function in adults with osteogenesis imperfecta. Clin Respir J. 2014;8(4):437–443.
  • Widmann RF, Bitan FD, Laplaza FJ, et al. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine. 1999;24(16):1673–1678.
  • McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Pathol. 1996;49(8):627–630.
  • Folkestad L, Hald JD, Canudas-Romo V, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016;31(12):2159–2166.
  • Yonko EA, Emanuel JS, Carter EM, et al. Respiratory impairment impacts QOL in osteogenesis imperfecta independent of skeletal abnormalities. Arch Osteoporos. 2020;15(1):153.
  • Folkestad L. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark. Danish Med J. 2018;65(4):1–51.
  • Ayadi ID, Hamida EB, Rebeh RB, et al. Perinatal lethal type II osteogenesis imperfecta: a case report. Pan Afr Med J. 2015;21:11.
  • Shapiro JR, Burn VE, Chipman SD, et al. Pulmonary hypoplasia and osteogenesis imperfecta type II with defective synthesis of alpha I(1) procollagen. Bone. 1989;10(3):165–171.
  • Thibeault DW, Pettett G, Mabry SM, et al. Osteogenesis imperfecta type IIA and pulmonary hypoplasia with normal alveolar development. Pediatr Pulmonol. 1995;20(5):301–306.
  • Barros CA, Rezende Gde C, Araujo Júnior E, et al. Prediction of lethal pulmonary hypoplasia by means fetal lung volume in skeletal dysplasias: a three-dimensional ultrasound assessment. J Matern Fetal Neonat Med. 2016;29(11):1725–1730.
  • Himakhun W, Rojnueangnit K, Prachukthum S. Perinatal lethal osteogenesis imperfecta in a Thai newborn: the autopsy and histopathogical findings. J Med Assoc Thai. 2012;95:S190–S194.
  • Pierce JA, Hocott JB, Ebert RV. Studies of lung collagen and elastin. Am Rev Respir Dis. 1959;80(1 Part 2):45–49.
  • Pierce JA, Hocott JB. Studies on the collagen and elastin content of the human lung. J Clin Invest. 1960;39(1):8–14.
  • Bradley KH, McConnell SD, Crystal RG. Lung collagen composition and synthesis. Characterization and changes with age. J Biol Chem. 1974;249(9):2674–2683.
  • Laurent GJ. Lung collagen: more than scaffolding. Thorax. 1986;41(6):418–428.
  • Burgeson RE, Nimni ME. Collagen types. Molecular structure and tissue distribution. Clin Orthop Relat Res. 1992;282:250–272.
  • Bienkowski RS, Gotkin MG. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med. 1995;209(2):118–140.
  • Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63. doi:10.1136/bmjebm-2017-110853. 29420178
  • Baglole CJ, Liang F, Traboulsi H, et al. Pulmonary and diaphragmatic pathology in collagen type I α1 mutant mice with osteogenesis imperfecta. Pediatr Res. 2018;83(6):1165–1171.
  • Baldridge D, Lennington J, Weis M, et al. Generalized connective tissue disease in Crtap−/− mouse. PLOS One. 2010;5(5):e10560.
  • Dimori M, Heard-Lipsmeyer ME, Byrum SD, et al. Respiratory defects in the CrtapKO mouse model of osteogenesis imperfecta. Am J Physiol Lung Cell Mol Physiol. 2020;318(4):L592–L605.
  • LoMauro A, Fraschini P, Pochintesta S, et al. Ribcage deformity and the altered breathing pattern in children with osteogenesis imperfecta. Pediatr Pulmonol. 2018;53(7):964–972.
  • Sanchis-Gimeno JA, Lois-Zlolniski S, María González-Ruiz J, et al. Association between ribs shape and pulmonary function in patients with Osteogenesis Imperfecta. J Adv Res. 2020;21:177–185.
  • Pan CH, Ma SC, Wu CT, et al. All pedicle screw fixation technique in correcting severe kyphoscoliosis in an osteogenesis imperfecta patient: a case report. J Spinal Disord Tech. 2006;19(5):368–372.
  • Kaplan L, Barzilay Y, Hashroni A, et al. Thoracic elongation in type III osteogenesis imperfecta patients with thoracic insufficiency syndrome. Spine. 2013;38(2):E94–E100.
  • Bronheim R, Khan S, Carter E, et al. Scoliosis and cardiopulmonary outcomes in osteogenesis imperfecta patients. Spine. 2019;44(15):1057–1063.
  • Khan SI, Yonko EA, Carter EM, et al. Cardiopulmonary status in adults with osteogenesis imperfecta: intrinsic lung disease may contribute more than scoliosis. Clin Orthopaed Relat Res. 2020;478:2833–2843.
  • Morikawa M, Fukuda Y, Terasaki Y, et al. Osteogenesis imperfecta associated with dendriform pulmonary ossification. Am J Respir Crit Care Med. 2016;193(4):460–461.
  • Madri JA, Furthmayr H. Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis. Hum Pathol. 1980;11(4):353–366.
  • Patino MG, Neiders ME, Andreana S, et al. Collagen: an overview. Implant Dent. 2002;11(3):280–285.
  • Gibson GJ, Pride NB, Davis J, et al. Exponential description of the static pressure-volume curve of normal and diseased lungs. Am Rev Respir Dis. 1979;120(4):799–811.
  • Koumbourlis AC. Scoliosis and the respiratory system. Paediatr Respir Rev. 2006;7(2):152–160.
  • Eekhoff EMW, Micha D, Forouzanfar T, et al. Collaboration around rare bone diseases leads to the unique organizational incentive of the Amsterdam Bone Center. Front Endocrinol. 2020;11:481.